The Center has dedicated biostatisticians who focus on large observational data analyses using sophisticated inferential methods to develop and test hypotheses related to the quality of cancer care in the United States. Datasets frequently employed include the SEER-Medicare data, indemnity Medicare data parts A, B, and D, the National Cancer Database, primary data underlying clinicaltrials.gov, the Nationwide Inpatient Sample, Blue Health Intelligence, as well as institutional encounter data and payment rate crosswalk data. These statisticians also provide institutional support for analyses of care redesign at Memorial Sloan Kettering that incorporate normalized cost and resource utilization data.
Jain RH, Schleicher SM, Atoria CL, Bach PB. Part B payment for drugs in Medicare: Phase 1 of CMS’ proposed pilot and its impact on oncology care. Evidence Driven Drug Pricing Project.2016 April 11.
Lipitz-Snyderman A, Klotz A, Gennarelli RL, Groeger J. A Population-Based Assessment of Emergency Department Observation Status for Older Adults With Cancer. J Natl Compr Canc Netw. 2017 Oct;15(10):1234-1239. doi: 10.6004/jnccn.2017.0160.
Feuerstein MA, Atoria CL, Pinheiro LC, Huang WC, Russo P, Elkin EB. Patterns of surveillance imaging after nephrectomy in the Medicare population. BJU Int. 2016 Feb;117(2):280-6. doi: 10.1111/bju.12980. Epub 2015 Jun 22.